Takara Bio Inc operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Takara Bio Inc with three other
companies in this sector in JAPAN :
Linical Company Limited
sales of 10.94 billion Japanese Yen [US$104.76 million]
of which 91%
was Cro Business),
Morishita Jintan Co., Ltd.
(9.77 billion Japanese Yen [US$93.63 million]
of which 75%
was Health Care Business), and
Shin Nippon Biomedical Laboratories Ltd
(14.56 billion Japanese Yen [US$139.50 million]
of which 90%
was Pre-Clinical Business).
Takara Bio Inc reported sales of ¥34.57 billion (US$331.13 million)
March of 2020.
decrease of 3.6%
versus 2019, when the company's sales were ¥35.84 billion.
Contributing to the drop in overall sales was the 6.1% decline
in Gene Medical Care, from ¥2.44 billion to ¥2.30 billion.
However, these declines were partially offset by the increase in sales of
Bio Support (up 2.2% to ¥32.27 billion)